Field Trip Health Ltd

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.

TORONTO, March 3, 2022 /PRNewswire/ -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic-assisted psychotherapy, today announced a strategic partnership with Cerebral, the fastest growing online mental health platform.

Field Trip Health and Cerebral Partner to Provide End-to-End Mental Health Care

Field Trip Health Ltd. (FTRP) CEO Joseph Del Moral on Q3 2022 - Earnings Call Transcript

Psychedelics-based company Field Trip Health Ltd. (TSX:FTRP) (NASDAQ:FTRP) reported its third fiscal quarter 2022 results for the three months ended December 31, 2021 and provided a business update.

Field Trip Health Posts 330% YoY Increase In Q3 Revenue

TORONTO, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; NASDAQ: FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, reported its third fiscal quarter 2022 results for the three months ended December 31, 2021 and provided a business update. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise specified.

Field Trip Health Ltd. Reports Third Fiscal Quarter 2022 Financial Results and Provides Business Update

Cybin

Mind Medicine MindMed

Media company Global Trac Solutions, Inc. (OTCP:PSYC) and authorities behind psychedelic news and information platform Psychedelic Spotlight, announced that Psychedelic Spotlight will host its first “CEO Roundtable” on Feb. 15. The event is scheduled to be streamed live on YouTube via The Psychedelic Investor channel, and will be moderated by James Hallifax, journalist and content director for Psychedelic Spotlight.

Cybin, MindMed, and Field Trip Health Headline PSYC's First CEO Round Table Event.

TORONTO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for the fiscal third quarter ended December 31, 2021, after market close on Tuesday, February 15, 2022.

Field Trip Health Ltd. Schedules Third Fiscal Quarter 2022 Financial Results Conference Call for February 16, 2022 at 8:30 AM ET

On Tuesday, three public companies in the psychedelics/biotech space announced significant milestones in their drug development pipelines. Field Trip Receives Notice Of Patent Allowance For Proprietary Psychedelic Molecule Field Trip Health (NASDAQ:FTRP) received a notice of allowance for a US patent application covering FT-104, its flagship psychedelic drug candidate.

Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana

The Allowed Claims include Composition of FT-104, which is a more soluble, stable prodrug form of the psychedelic molecule 4-HO-DiPT The Allowed Claims include Composition of FT-104, which is a more soluble, stable prodrug form of the psychedelic molecule 4-HO-DiPT

Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development

TORONTO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip's Co-Founder and CEO, Joseph del Moral, and Chief Scientific Officer, Dr. Nathan Bryson, will participate in a virtual fireside chat at the H.C. Wainwright Bioconnect Virtual Conference taking place January 10-13, 2022.

Field Trip Health Ltd. to Participate in H.C.

Atai Life Sciences BV

COMPASS Pathways

Psychedelic substances are often grouped together with cannabis, but there are some important distinctions. ATAI, CMPS and FTRP are some of the best stocks in the space.

3 Psychedelic Stocks to Play the Shroom Boom

This Expansion of Field Trip Services Will Help The Company Become a Leading Center For Psychedelic Clinical Trials This Expansion of Field Trip Services Will Help The Company Become a Leading Center For Psychedelic Clinical Trials

Field Trip Launches Site Management Organization (SMO) Services, Hires Stéphan Côté as Head of Quality

Ameri Holdings

GH Research PLC

Jaguar Health

Seelos Therapeutics

The usage of psychedelics like psilocybin, LSD, ketamine, and others are becoming more mainstream, especially with the initial steps to legalization getting moving across a number of states in the U.S. As a result, the psychedelics market is projected to grow 12.4% annually, reaching $10.75 billion in 2027.

9 Psychedelic Stocks to Watch For 2022

TORONTO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that management will present at H.C. Wainwright's 2nd Annual Psychedelics Conference and Stifel's 2nd Annual Future of Healthcare Conference in December.

Field Trip Health Ltd. to Participate in Upcoming Conferences in December 2021

Psychedelic drugs could be a major game-changer when it comes to treating mental illness. All as psilocybin, LSD, and MDMA show progress.

3 Psychedelic Stocks for Potential Out-of-This-World Gains

Field Trip Health Ltd.'s (FTRP) CEO Joseph del Moral on Q2 2022 Results - Earnings Call Transcript

TORONTO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; NASDAQ: FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, reported its second fiscal quarter 2022 results for the three months ended September 30, 2021 and provided a business update. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise specified.

Field Trip Health Ltd. Reports Second Fiscal Quarter 2022 Financial Results and Provides Business Update

TORONTO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that during the month of November management will attend the Microdose Wonderland: Miami Conference and present at the Stifel 2021 Virtual Healthcare Conference and the Jefferies London Healthcare Conference.

Field Trip Health Ltd. to Participate in Upcoming Conferences in November 2021

TORONTO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for the fiscal second quarter ended September 30, 2021, after market close on Monday, November 15, 2021.

Field Trip Health Ltd. Schedules Second Fiscal Quarter 2022 Financial Results Conference Call for Tuesday, November 16, 2021 at 8:30 AM ET

With the Opening of Three New Clinics, Field Trip Health Builds Momentum for the Psychedelic Renaissance in the Mental Health Field With the Opening of Three New Clinics, Field Trip Health Builds Momentum for the Psychedelic Renaissance in the Mental Health Field

Field Trip Health Ltd. Continues Expansion With Psychedelic-Assisted Therapy Centers in Seattle, Vancouver and Fredericton

Field Trip Health Ltd (NASDAQ: FTRP) is a global leader in psychedelic therapies, and over the past year, bringing eye-popping gains to investors' portfolios. Since October 2020, Field Trip Health stock's one-year return has outperformed a number of the world's most popular tech and energy companies: Nio Inc - ADR (NYSE: NIO), Advanced Micro Devices, Inc. (NASDAQ: AMD), NVIDIA Corporation (NASDAQ: NVDA), General Electric Company (NYSE: GE).

This Psychedelic Therapies Stock Has A Better One-Year Return Than Nio, AMD, Nvidia And GE

TORONTO, Oct. 12, 2021 /PRNewswire/ -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; Nasdaq: FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, today announced that Joseph del Moral, Co-Founder & CEO of Field Trip, will present at the KCSA Psychedelics Investor Conference to be held at VirtualInvestorConferences.com on Wednesday, October 13 th at 12:30pm ET.

Field Trip Health Ltd. To Present At The KCSA Psychedelics Virtual Investor Conference On October 13th

TORONTO, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; Nasdaq: FTRP) ("Field Trip"), today announced the voting results from its Annual General and Special Meeting of Shareholders held on Friday, September 24, 2021. A total of 59.09% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.

Field Trip Health Announces Voting Results From the Annual General and Special Meeting of Shareholders

TORONTO, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; Nasdaq: FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, today announced it will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit, the Maxim Group Mental Health Conference and the Cantor Virtual Global Health Conference in September 2021.

Field Trip Health Ltd. to Participate in Four Investor Conferences in September

Anita H. Clayton, MD, joins Scientific Advisory Board Anita H. Clayton, MD, joins Scientific Advisory Board

Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104

The first state to legalize cannabis for medical use was California, in 1996. In 2001, medical marijuana was approved in Canada.

News for Field Trip Health Ltd Stock (FTRP)